Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-negative Surveillance Outcome Program (GnSOP)...

The Australian Group on Antimicrobial Resistance (AGAR) performs regular period-prevalence studies to monitor changes in antimicrobial resistance in selected enteric gram-negative pathogens. From 1 January 2024 to 31 December 2024, fifty-five hospitals across Australia participated in the Australian Gram-negative Surveillance Outcome Program (GnSOP). A total of 10,340 isolates, comprising Enterobacterales (9,376; 90.9%), Pseudomonas aeruginosa (804; 7.7%) and Acinetobacter species (160; 1.4%), were tested using commercial automated methods. The results were analysed using European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints (January 2025). Key resistances reported are to the third-generation cephalosporin ceftriaxone in 14.9% of Escherichia coli and 10.5% of Klebsiella pneumoniae complex isolates. Resistance rates to ciprofloxacin were 15.4% for E. coli; 9.7% for the K. pneumoniae complex; 3.8% for the Enterobacter cloacae complex; and 8.8% for P. aeruginosa. Resistance rates to piperacillin-tazobactam were 7.5%, 10.3%, 25.2%, and 13.6% for the same four species/complexes, respectively. Thirty-nine Enterobacterales isolates from 38 patients were shown to harbour a carbapenemase gene: 21 with a bla_NDM gene (bla_NDM-5 [8]; bla_NDM-1 [7]; bla_NDM-7 [6]); eight with bla_IMP-4; four with a bla_OXA-181-like gene (bla_OXA-181 [2]; bla_OXA-484 [1]; bla_OXA-1205 [1]); three with a bla_OXA-48-like gene (bla_OXA-48 [2]; bla_OXA-244); two with bla_KPC-2; and one with bla_NDM-5 + bla_OXA-484. Carbapenemase genes were also detected in two P. aeruginosa isolates (bla_NDM-1 [1]; bla_GES-5 [1]).